Tiger Brokers

Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study

Reuters
Mar 19
<a href="https://laohu8.com/S/ANVS">Annovis Bio</a> partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study
  • Annovis partnered with NeuroRPM to deploy an FDA-cleared AI platform for movement-data collection in an ongoing Parkinson’s disease study.
  • The platform is intended to monitor bradykinesia, tremor, and dyskinesia using mobile and wearable applications.
  • Annovis said the NeuroRPM data will be used as a digital biomarker to track symptom changes during the study.
  • The open-label study is enrolling across 25 U.S. sites and is designed to evaluate buntanetap over 36 months.
  • The trial has enrolled 90 of an estimated 500 participants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190730PRIMZONEFULLFEED9674577) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10